



C.F.T.C.
OFFICE OF THE SECRETARIAT
2010 AUG 3 AM 11 27

August 3, 2010

VIA E-MAIL

Mr. David Stawick
Office of the Secretariat
Commodity Futures Trading Commission
Three Lafayette Centre
1155 21st Street, N.W.
Washington, D.C. 20581

**Re: Rule Certification. Commodity Exchange, Inc. Submission #10-214:
Notification of Listing of Additional Contract Months for COMEX miNY Gold
Futures and COMEX miNY Silver Futures Contracts Listed on CME Globex®**

Dear Mr. Stawick:

The Commodity Exchange, Inc. ("COMEX" or "Exchange") is notifying the Commodity Futures Trading Commission ("CFTC" or "Commission") that it is self-certifying the listing of additional contract months for (1) COMEX miNY Gold Futures contract (Chapter 911; code QO) pursuant to Rule 911.04 "Contract Months" and (2) COMEX miNY Silver Futures contract (Chapter 912; code QI) pursuant to Rule 912.04 "Contract Months". The COMEX miNY Gold Futures and COMEX miNY Silver Futures contracts are listed on CME Globex.

The additional contract months proposed to be listed are as follows:

COMEX miNY Gold Futures

February 2012
April 2012
June 2012
August 2012
October 2012
December 2012

COMEX miNY Silver Futures

January 2012
March 2012
May 2012
July 2012
September 2012
December 2012

Currently, the last listed trading month for each of COMEX miNY Gold Futures and COMEX miNY Silver Futures contracts is the December 2011 contract month.

The expanded contract months for each of COMEX miNY Gold Futures and COMEX miNY Silver Futures, listed above, will be available for trading on CME Globex effective trade date Monday, August 30, 2010.

Pursuant to Section 5c(c) of the Commodity Exchange Act ("Act") and CFTC Rule 40.6, the Exchange hereby certifies that the listing of additional contract months complies with the Act, including regulations under the Act. These changes will be made effective on Monday, August 30, 2010.

Should you have any questions concerning the above, please contact Robert A. Levin at (212)-299-2390 or the undersigned at (212) 299-2200.

Sincerely,
/s/ Christopher K. Bowen
MD, Chief Regulatory Counsel